Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by stock analysts at Royal Bank of Canada from an ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...

BofA lowered the firm’s price target on Sarepta (SRPT) to $179 from $210 and keeps a Buy rating on the shares. Following the news of the ...

As director of the FDA's Center for Biologics Evaluation and Research, Marks has publicly supported programs that expedited ...

Mizuho Securities analyst Uy Ear maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is ...

More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the ...

Biotech stocks plunge after Dr. Peter Marks resigns from FDA, citing disputes with RFK Jr. over vaccines and drug approvals.

Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.

Sarepta Therapeutics is down 48.6% since the beginning of the year, and at $63.75 per share, it is trading 61.1% below its 52-week high of $163.85 from June 2024.